Javascript must be enabled to continue!
Prevention of immunoglobulin production by allotypedependent T cells
View through CrossRef
AbstractAdoptive lymphocyte transfers between Iga, Igb and Igd allotype‐congenic mouse strains revealed host barriers against the production of certain donor allotypes. First, as recipients of Igb cells, Iga and Igd mice permitted the production of donor Ig‐4b but not that of Ig‐lb. The apparent mediators of this Ig‐lb barrier were T cells specific for Ig‐lb determinants on B cells. Additional cell transfers showed Iga mice to have a second barrier against allotype production by Igd donor cells. Reciprocal cell transfers showed Igb and Igd mice to have comparatively weak barriers against Iga‐producing cells.As host barriers were absent in mice deficient for T cells (athymic nude mice), it appears that they are T cell‐mediated. Further, the allotype‐dependence of such barriers means that the antigens responsible must be under the control of allotype‐linked genes. The regulatory implications of this for the immune system are discussed.
Title: Prevention of immunoglobulin production by allotypedependent T cells
Description:
AbstractAdoptive lymphocyte transfers between Iga, Igb and Igd allotype‐congenic mouse strains revealed host barriers against the production of certain donor allotypes.
First, as recipients of Igb cells, Iga and Igd mice permitted the production of donor Ig‐4b but not that of Ig‐lb.
The apparent mediators of this Ig‐lb barrier were T cells specific for Ig‐lb determinants on B cells.
Additional cell transfers showed Iga mice to have a second barrier against allotype production by Igd donor cells.
Reciprocal cell transfers showed Igb and Igd mice to have comparatively weak barriers against Iga‐producing cells.
As host barriers were absent in mice deficient for T cells (athymic nude mice), it appears that they are T cell‐mediated.
Further, the allotype‐dependence of such barriers means that the antigens responsible must be under the control of allotype‐linked genes.
The regulatory implications of this for the immune system are discussed.
Related Results
Immunoassay of serum polypeptide hormones by using 125I-labelled anti(-immunoglobulin G) antibodies
Immunoassay of serum polypeptide hormones by using 125I-labelled anti(-immunoglobulin G) antibodies
1. A technique for indirectly labelling antibodies to polypeptide hormones, by combining them with radioactively labelled anti-(immunoglobulin G) is described. (a) 125I-labelled an...
Successful transfection of Lymphoblastoid cell line (Preprint)
Successful transfection of Lymphoblastoid cell line (Preprint)
BACKGROUND
Immortalization is the stage that the cell goes through before full transformation [1]. Human resting B lymphocytes from peripheral blood are eas...
Subpopulations of Chicken B Lymphocytes
Subpopulations of Chicken B Lymphocytes
Abstract
Immunoglobulin-synthesizing cells from the spleen and bursa were fractionated by the 1 × G sedimentation velocity technique and characterized by their abili...
MARS-seq2.0: an experimental and analytical pipeline for indexed sorting combined with single-cell RNA sequencing v1
MARS-seq2.0: an experimental and analytical pipeline for indexed sorting combined with single-cell RNA sequencing v1
Human tissues comprise trillions of cells that populate a complex space of molecular phenotypes and functions and that vary in abundance by 4–9 orders of magnitude. Relying solely ...
Stem cells
Stem cells
What is a stem cell? The term is a combination of ‘cell’ and ‘stem’. A cell is a major category of living thing, while a stem is a site of growth and support for something else. In...
A randomized multicenter study: safety and efficacy of mini‐pool intravenous immunoglobulin versus standard immunoglobulin in children aged 1‐18 years with immune thrombocytopenia
A randomized multicenter study: safety and efficacy of mini‐pool intravenous immunoglobulin versus standard immunoglobulin in children aged 1‐18 years with immune thrombocytopenia
BACKGROUNDBecause there is a global shortage of intravenous immunoglobulin, there is a need for new products to fill the gap.STUDY DESIGN AND METHODSThis was a multicenter, open‐la...
Nature Products Enhance NKG2D Ligands Expression of CD123+CD34+CD38− Leukemia Stem Cells for Stimulating Cytotoxicity of NKG2D+ Cells to Themselves
Nature Products Enhance NKG2D Ligands Expression of CD123+CD34+CD38− Leukemia Stem Cells for Stimulating Cytotoxicity of NKG2D+ Cells to Themselves
Abstract
CD123+CD34+CD38− leukemia cells regarded as leukemia stem cells, not only refractory to chemotherapeutics but also resistant to immune response such as cyto...
Developing “Off-the-Shelf” CLL1 CAR-DNT Therapeutics for the R/R Acute Myeloid Leukemia
Developing “Off-the-Shelf” CLL1 CAR-DNT Therapeutics for the R/R Acute Myeloid Leukemia
Background: Acute myeloid leukemia (AML) is one of the most common and highly heterogeneous hematological malignancy. The prognosis is poor especially for the elderly patients. For...

